Design in nonlinear mixed effects models: Optimization using the Fedorov–Wynn algorithm and power of the Wald test for binary covariates

We extend the methodology for designs evaluation and optimization in nonlinear mixed effects models with an illustration of the decrease of human immunodeficiency virus viral load after antiretroviral treatment initiation described by a bi‐exponential model. We first show the relevance of the predicted standard errors (SEs) given by the computation of the population Fisher information matrix using the R function PFIM, in comparison to those computed with the stochastic approximation expectation–maximization algorithm, implemented in the Monolix software. We then highlight the usefulness of the Fedorov–Wynn (FW) algorithm for designs optimization compared to the Simplex algorithm. From the predicted SE of PFIM, we compute the predicted power of the Wald test to detect a treatment effect as well as the number of subjects needed to achieve a given power. Using the FW algorithm, we investigate the influence of the design on the power and show that, for optimized designs with the same total number of samples, the power increases when the number of subjects increases and the number of samples per subject decreases. A simulation study is also performed with the nlme function of R to confirm this result and show the relevance of the predicted powers compared to those observed by simulation. Copyright © 2007 John Wiley & Sons, Ltd.

[1]  Jerry R. Nedelman,et al.  On some “disadvantages” of the population approach , 2005, The AAPS Journal.

[2]  France Mentré,et al.  Extension of the SAEM algorithm to left-censored data in nonlinear mixed-effects model: Application to HIV dynamics model , 2006, Comput. Stat. Data Anal..

[3]  Mats O. Karlsson,et al.  Comparison of some practical sampling strategies for population pharmacokinetic studies , 1996, Journal of Pharmacokinetics and Biopharmaceutics.

[4]  Dongwoo Kang,et al.  Sample Size Computations for PK/PD Population Models , 2005, Journal of Pharmacokinetics and Pharmacodynamics.

[5]  Goonaseelan Pillai,et al.  Non-Linear Mixed Effects Modeling – From Methodology and Software Development to Driving Implementation in Drug Development Science , 2005, Journal of Pharmacokinetics and Pharmacodynamics.

[6]  Hulin Wu,et al.  Modeling Long-Term HIV Dynamics and Antiretroviral Response: Effects of Drug Potency, Pharmacokinetics, Adherence, and Drug Resistance , 2005, Journal of acquired immune deficiency syndromes.

[7]  Marc Lavielle,et al.  Maximum likelihood estimation in nonlinear mixed effects models , 2005, Comput. Stat. Data Anal..

[8]  Hulin Wu,et al.  Statistical methods for HIV dynamic studies in AIDS clinical trials , 2005, Statistical methods in medical research.

[9]  Brian Whiting,et al.  Experimental design and efficient parameter estimation in population pharmacokinetics , 1990, Journal of Pharmacokinetics and Biopharmaceutics.

[10]  Dongwoo Kang,et al.  A sample size computation method for non‐linear mixed effects models with applications to pharmacokinetics models , 2004, Statistics in medicine.

[11]  France Mentré,et al.  Optimization of Individual and Population Designs Using Splus , 2003, Journal of Pharmacokinetics and Pharmacodynamics.

[12]  Stephen B. Duffull,et al.  Prospective Evaluation of a D-Optimal Designed Population Pharmacokinetic Study , 2003, Journal of Pharmacokinetics and Pharmacodynamics.

[13]  France Mentré,et al.  Population Pharmacokinetic Analysis and Optimization of the Experimental Design for Mizolastine Solution in Children , 2001, Journal of Pharmacokinetics and Pharmacodynamics.

[14]  Kathryn Chaloner,et al.  D- and c-optimal designs for exponential regression models used in viral dynamics and other applications , 2003 .

[15]  France Mentré,et al.  Further Developments of the Fisher Information Matrix in Nonlinear Mixed Effects Models with Evaluation in Population Pharmacokinetics , 2003, Journal of biopharmaceutical statistics.

[16]  France Mentré,et al.  Fisher information matrix for non‐linear mixed‐effects models: evaluation and application for optimal design of enoxaparin population pharmacokinetics , 2002, Statistics in medicine.

[17]  Stephen B. Duffull,et al.  The use of simulated annealing for finding optimal population designs , 2002, Comput. Methods Programs Biomed..

[18]  Hulin Wu,et al.  Design of viral dynamic studies for efficiently assessing potency of anti-HIV therapies in AIDS Clinical Trials , 2002 .

[19]  V. Carey,et al.  Mixed-Effects Models in S and S-Plus , 2001 .

[20]  A. Ding,et al.  Assessing antiviral potency of anti-HIV therapies in vivo by comparing viral decay rates in viral dynamic models. , 2001, Biostatistics.

[21]  H Wu,et al.  Population HIV‐1 Dynamics In Vivo: Applicable Models and Inferential Tools for Virological Data from AIDS Clinical Trials , 1999, Biometrics.

[22]  I. Marschner Design of HIV viral dynamics studies. , 1998, Statistics in medicine.

[23]  V De Gruttola,et al.  Estimation of HIV dynamic parameters. , 1998, Statistics in medicine.

[24]  Alan S. Perelson,et al.  Hepatitis C Viral Dynamics in Vivo and the Antiviral Efficacy of Interferon-α Therapy , 1998 .

[25]  A S Perelson,et al.  Hepatitis C viral dynamics in vivo and the antiviral efficacy of interferon-alpha therapy. , 1998, Science.

[26]  Alain Mallet,et al.  Optimal design in random-effects regression models , 1997 .

[27]  Eric Walter,et al.  Identification of Parametric Models: from Experimental Data , 1997 .

[28]  D. Bates,et al.  Approximations to the Log-Likelihood Function in the Nonlinear Mixed-Effects Model , 1995 .

[29]  W. Näther Optimum experimental designs , 1994 .

[30]  P. Laycock,et al.  Optimum Experimental Designs , 1995 .

[31]  D. Bates,et al.  Nonlinear mixed effects models for repeated measures data. , 1990, Biometrics.

[32]  A. Mallet A maximum likelihood estimation method for random coefficient regression models , 1986 .

[33]  T. Louis Finding the Observed Information Matrix When Using the EM Algorithm , 1982 .

[34]  W. J. Studden,et al.  Theory Of Optimal Experiments , 1972 .

[35]  L. Sheiner,et al.  Modelling of individual pharmacokinetics for computer-aided drug dosage. , 1972, Computers and biomedical research, an international journal.

[36]  F J Lewis,et al.  Continuous patient monitoring with a small digital computer. , 1972, Computers and biomedical research, an international journal.

[37]  H. Wynn Results in the Theory and Construction of D‐Optimum Experimental Designs , 1972 .

[38]  J. Kiefer,et al.  Optimum Designs in Regression Problems , 1959 .